DDO-02267
DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 increases N6-methyladenosine (m6A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase[1].
Product Specifications
CAS Number
2919768-58-2
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Fat Mass and Obesity-associated Protein (FTO)
Related Pathways
Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=CC1=C(O)C2=C(C=CC=C2)C(S(=O)(NC(C3=NC=CC(C(O)=O)=C3)=O)=O)=C1
Molecular Formula
C18H12N2O7S
Molecular Weight
400.36
References & Citations
[1]Fei WL, et al. Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5. Eur J Med Chem. 2024 Dec 23;284:117183.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
